Pathologic complete response of advanced hepatoid adenocarcinoma of the stomach following immuno-chemotherapy and conversion surgery: a rare case report and review of the literature
HAS is a highly invasive malignant tumor of the stomach. The dynamic changes in AFP serve as a reliable indicator for detecting HAS, evaluating treatment efficacy, and predicting recurrence. In advanced HER-2-negative, PD-L1 CPS<5, pMMR-type HAS, employing a conversion therapy regimen combining sintilimab with Nab-paclitaxel, oxaliplatin, and S-1 may reduce tumor staging, enhance conversion therapy success rates, and prolong survival.
Authors
- Yaoqi Li (ORCID: https://orcid.org/0000-0001-6540-395X)
- Mingxu Da (ORCID: https://orcid.org/0000-0001-9181-6088)
- Dong Wang (ORCID: https://orcid.org/0000-0001-6585-2704)
- Jichun Ma
- Changyuan Yu (ORCID: https://orcid.org/0000-0002-3185-0441)
- You Wang (ORCID: https://orcid.org/0000-0002-5521-5039)
- Hong Ma
Institutions
- Gansu University of Traditional Chinese Medicine (CN)
- Shanghai Liangyou (China) (CN)
- Gansu Provincial Hospital (CN)
- Cixian People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-02
- DOI
- https://doi.org/10.3389/fonc.2025.1648766
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Gansu Province